Abstract
Parkinson disease progression is associated with the development of levodopa short-duration responses and dyskinesias, as well as gait freezing. Levodopa dose adjustment and adjunctive treatment with dopamine agonists form the major therapeutic strategies. Catechol O-methyltransferase inhibitors are also appropriate considerations, whereas other drugs, including selegiline, amantadine, anticholinergic agents, and propranolol, have a more minor role.
MeSH terms
-
Amantadine / therapeutic use
-
Antiparkinson Agents / administration & dosage
-
Antiparkinson Agents / adverse effects
-
Antiparkinson Agents / therapeutic use*
-
Benzophenones / therapeutic use
-
Carbidopa / therapeutic use
-
Catechol O-Methyltransferase Inhibitors
-
Catechols / therapeutic use
-
Cholinergic Antagonists / therapeutic use
-
Dopamine Agonists / therapeutic use
-
Dose-Response Relationship, Drug
-
Drug Combinations
-
Dyskinesia, Drug-Induced / etiology
-
Enzyme Inhibitors / therapeutic use
-
Humans
-
Levodopa / therapeutic use
-
Nitriles
-
Nitrophenols
-
Parkinson Disease, Secondary / drug therapy*
-
Propranolol / therapeutic use
-
Randomized Controlled Trials as Topic
-
Selegiline / therapeutic use
-
Tolcapone
Substances
-
Antiparkinson Agents
-
Benzophenones
-
Catechol O-Methyltransferase Inhibitors
-
Catechols
-
Cholinergic Antagonists
-
Dopamine Agonists
-
Drug Combinations
-
Enzyme Inhibitors
-
Nitriles
-
Nitrophenols
-
carbidopa, levodopa drug combination
-
Selegiline
-
Levodopa
-
entacapone
-
Propranolol
-
Amantadine
-
Tolcapone
-
Carbidopa